Epitel, a digital health company developing advanced AI-driven wireless brain health technologies focused on seizure detection and diagnosis, raised $26 million in Series B financing co-led by Catalyst Health Ventures and Genoa Ventures, with participation from new and existing investors.
According to Epitel, the fresh funding will drive commercial expansion of its fully wireless FDA-cleared EEG system, making AI-driven remote brain monitoring more widely available to patients and providers.
Commenting on the fundraise, Steve Pacelli, President & CEO of Epitel, said: “Closing this Series B round represents a pivotal milestone for our team. With these resources, we are aggressively building out our commercial footprint by expanding our dedicated field team to get REMI into the hands of those who will most benefit from it.”
In the United States, 9.2 million Americans experience seizures annually, yet 40 percent lack access to EEG, in part because only 27 percent of U.S. hospitals have EEG capacity.
Steve Pacelli said: “Millions of Americans with suspected seizures still face significant barriers to diagnosis because access to EEG remains limited, particularly outside major medical centers. We built the REMI Remote EEG Monitoring System to help close that gap by bringing longer-term neurological monitoring closer to patients and helping clinicians efficiently review the data needed to make a diagnosis.”